Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease Wednesday, April 1: Animal and in vitro studies on TNX-801 (horsepox, live virus vaccine) for the prevention of smallpox and mpox Wednesday, April 1: Horsepox as a modular antigen-delivery system for broad and sustained immunity in novel vaccines to protect against other pathogens BERKELEY HEIGHTS, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced an oral presentation of Phase 1 data on TNX-4800 (formerly known as mAb 2217LS) 1,2 , a long-acting human monoclonal antibody (mAb) that targets the outer surface protein A (OspA) of Borrelia burgdorferi , the causative agent of Lyme disease in humans in the U.S., at the World Vaccine Congress Washington 2026 held in Washington, D.C., March 30-April 2, 2026. The Company's Farooq Nasar, PhD, Director, Virology will present data on TNX-801, the Company's attenuated, live orthopoxvirus (horsepox) vaccine candidate with the potential capability to protect against smallpox and mpox. Finally, Christopher Cooper, PhD, Director, Immunology at Tonix will serve as moderator on a panel discussing modular antigen-delivery systems in novel pox-based vaccines. TNX-4800 Presentation Details Title: A Long-Acting Monoclonal Antibody for Seasonal Prevention of Lyme Disease Location: Room 202B Date and Time: March 30, 2026, 10:10 a.m. ET Session Category: Measuring Breadth & Emerging Targets Presenters: Mark S. Klempner, MD, Professor of Medicine at UMass Chan Medical School, inventor of TNX-4800, and Principal Investigator of the study Other Session Details Title: A Live Attenuated, Minimally Replicative MPOX Vaccine Location: Room 202A, Level 2 Date and Time: April 1, 2026, 10:10 am ET Session Category: Emerging & Re-Emerging Diseases Presenter: Farooq Nasar, PhD, Director, Virology, Research and Development Center (RDC), Tonix Pharmaceuticals Title: Poxvirus as a Modular Antigen-Delivery System for Broad and Sustained Immunity Location: Room 20A, Level 2 Date and Time: April 1, 2026, 3:25 p.m. ET Session Category: Emerging & Re-Emerging Diseases Moderator: Christopher Cooper, PhD, Director, Immunology, RDC, Tonix Pharmaceuticals About TNX-4800 TNX-4800 (formerly known as mAb 2217LS) is a human monoclonal antibody with an engineered extended half-life that targets the outer-surface protein A (OspA) on Lyme-causing Borrelia bacteria. When TNX-4800-containing blood is ingested by the tick, TNX-4800 kills and blocks the maturation of Borrelia burgdorferi in the mid-gut of infected deer ticks. The Company in-licensed TNX-4800 from UMass Chan Medical School in 2025. Published work in animals showed that TNX-4800 was 95% effective in preventing infection after a six-day challenge with ticks infected with Borrelia burgdorferi . 1 TNX-4800 was derived from mAb 2217 by amino acid substitutions in its crystallizable fragment (Fc) domain which serve to prolong the serum half-life. A single administration in the Spring is designed to potentially provide immunity within two days and maintain protective antibody titers for the ... Full story available on Benzinga.com
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
